n CME : Your SA Journal of CPD - Pharm info

Volume 22, Issue 8
  • ISSN : 0256-2170



Extracted from text ... Should we consider the routine administration of ACE inhibitors such as perindopril in all people with coronary artery disease (CAD)? 'Yes, ' said Professor Willem Remme of the Sticares Cardiovascular Research Institute, Rhoon, the Netherlands, as he concluded his presentation on the EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) study to doctors around South Africa. The EUROPA study was designed to assess whether the long-term administration of perindopril, added to standard preventive therapy, would reduce cardiovascular events in a broad spectrum of patients with definite evidence of CAD, irrespective of their ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error